Source: Adimmune Corp.

Adimmune Corporation (4142) announced today the company is providing the Taiwan government with over 3.27 million doses of quadrivalent influenza vaccine (QIV), a total of TWD 786 million, taking up more than 50% of the procurement of Taiwan Centers for Disease Control (CDC), the Ministry of Health and Welfare. For private sector, Adimmune is to provide about 100,000 doses of QIV to ensure the public health and safety in Taiwan.

Adimmune is expanding its international market by the marketing authorizations granted by the countries in Asia, North America, and Europe. While the influenza antigen and vaccine are being sold to more countries and the increases in volume, it is estimated that the revenue of overseas market will be the driving force this year and exceed the revenue of the domestic one for the first time.

Adimmune is a partner of WHO’s Pandemic Influenza Preparedness Framework (PIP Framework) and, in 2012, has become a member of the IFPMA Influenza Vaccine Supply International Task Force, among others including Sanofi, GSK, and 15 other major influenza vaccine manufacturers. Task force members are invited to participate in the annual seasonal influenza strain selection meetings to obtain the latest virus surveillance information and to exchange their views. As the only influenza manufacturer in Taiwan, Adimmune has a unique advantage in responding to future outbreaks and bringing forward next generation vaccine on a timely basis.